Abstract
Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
CNS & Neurological Disorders - Drug Targets
Title:Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders
Volume: 12 Issue: 5
Author(s): Shafiqur Rahman
Affiliation:
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
Abstract: Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Export Options
About this article
Cite this article as:
Rahman Shafiqur, Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050011
DOI https://dx.doi.org/10.2174/1871527311312050011 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology In Vitro and In Vivo Transformations of Lutein
Mini-Reviews in Organic Chemistry A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice
Current Alzheimer Research Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design GABA and Neuroactive Steroid Interactions in Glia: New Roles for Old Players?
Current Neuropharmacology Molecular Biology of T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Enhanced Transdermal Delivery of Epidermal Growth Factor Facilitated by Dual Peptide Chaperone Motifs
Protein & Peptide Letters Histamine as an Anticonvulsant Inhibitory Neurotransmitter
Current Neuropharmacology Effect of Infertility on the Sexual Function of Couples: State of the Art
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Is There a Place for Drug Combination Strategies Using Clinical Pharmacology Attributes? – Review of Current Trends in Research
Current Clinical Pharmacology Characterization of Graphs for Protein Structure Modeling and Recognition of Solubility
Current Bioinformatics Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer’s Disease?
Current Alzheimer Research Conference Report
CNS & Neurological Disorders - Drug Targets Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis
Current Medicinal Chemistry The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Neuropsychiatric Aspects in Men with Klinefelter Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets